Streptococcus pneumoniae (S. pneumoniae)
is a leading cause of human disease
AFX3772 aims to protect against 24 of its pneumococcal serotypes
As you know, S. pneumoniae is a major contributor of illness ranging from the common, such as acute otitis media, to the serious, such as meningitis and bacteremia. Its polysaccharide (PS) encapsulation leads to a strong and potentially threatening virulence.
AFX3772 aims to provide broad and durable extended protection against S. pneumoniae.
The study of AFX3772 is a Phase 2, proof-of-concept study to support advancement of AFX3772 into Phase 3 pediatric clinical development.